Gelonghui, March 30, 丨 Xianjian Technology (01302.HK) announced that for the year ending December 31, 2021, the company's revenue was 925 million yuan, an increase of 44.1% over the previous year; gross profit was about 750 million yuan, an increase of 45.7% over the previous year; excluding a number of non-recurring projects, the company's owners should account for a net profit of 324 million yuan, an increase of 76.8% over the previous year.

The increase in revenue was mainly due to increased sales revenue of laminating stents, CERA blockers, and Lambre left ventricular occlusion.

Compared with the same period in 2020, the company's domestic sales increased by 43.6%, mainly due to the fact that the COVID-19 situation in mainland China has been contained, economic activity has resumed after strict epidemic control measures have been adopted; the penetration rate of the company's products into the domestic market has increased. Although the COVID-19 situation in most overseas markets is still unstable, the Group's overseas sales increased by 46.4% compared to the same period in 2020, mainly due to the company's adoption of effective overseas marketing strategies.

Intellectual property is an important intangible asset of the Group and an internal driving force for the company to enhance its core competitiveness in the medical device market. During the year, the Group submitted 252 patent applications and 156 patents were approved. As of December 31, 2021, the Group has submitted a total of 1,529 patent applications, of which 584 have been approved.

In 2022, the Group will continue to closely monitor the latest developments in the epidemic and effectively strengthen cost and working capital management to ensure the company's sustainable development. At the same time, the company will operate the company's existing business with prudent and pragmatic guidelines, actively seek investment opportunities that can maximize shareholders' interests, and diversify business risks by expanding revenue sources.